12:00 AM
 | 
Aug 12, 2013
 |  BC Week In Review  |  Company News  |  Deals

Merck KGaA, Cancer Research U.K., Cardiff University, The Institute of Cancer Research deal

Merck's Merck Serono S.A. unit received rights to develop preclinical molecules against the Wnt pathway to treat cancer discovered under a completed four-year research collaboration between the unit, the institute, Cardiff and Cancer Research's Cancer...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >